F-Prime Capital

Bluebird Kids Health is a pediatric healthcare provider that aims to build a healthier future for children. It offers a value-based care model, delivering comprehensive, evidence-based care tailored to each family's needs. Services include nutrition support, sleep training, treatments for common ailments like rashes and viruses, all aimed at reducing medical costs and providing personalized care. The company is also developing a proprietary technology platform, enhanced by AI, to proactively manage and coordinate treatment, further simplifying the experience for its clinical team.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Based on our deep science and focused on patients in need.

Shift Bioscience employs simulation-guided techniques to identify safer gene factors for cellular rejuvenation, aiming to develop a drug family that treats multiple age-related diseases. Its high-throughput aging biomarker enables accurate cell simulations, with the goal of making full health in old age accessible via prescription.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Amber Therapeutics specializes in developing advanced bioelectronic therapies that can sense and adapt, aiming to enhance clinical outcomes for patients with functional disorders of the peripheral nervous system.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Founded in 2019, Engrail Therapeutics is dedicated to developing and commercializing neuro drugs. Its primary focus is on treating diseases related to the nervous system. The company's flagship compound, ENX-101, is a preclinical modulator of a receptor for GABA, a neurotransmitter in the brain.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

OnCusp Therapeutics is a biopharmaceutical company dedicated to accelerating oncology medication innovation globally. It focuses on translating preclinical drug candidates into clinical proof-of-concept stage and advancing them for rapid global early clinical development.

PlasmaGen Biosciences Pvt. Ltd., established in 2010 and based in Bengaluru, India, is a biopharmaceutical company specializing in plasma protein therapies. The company manufactures a range of products including PlasmaGlob and AlbuMax, brands of Normal Human Immunoglobulin for Intravenous use, PlasmaRho-D I.V. for Rh immunization suppression, PlasmaRAB for rabies infection prophylaxis, PlasmaHep for hepatitis B exposure, VerBumin for conditions like hypovolemic shock and burns, and Gammafact-VIII. These products cater to various medical fields such as hematology, oncology, immunology, pediatrics, rheumatology, dermatology, and neurology. The company serves clinicians, medical practitioners, corporate hospitals, and government institutions.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

ARTBIO is a biotechnology company developing a new class of alpha radioligand medicines for cancer treatment. It focuses on radioligand therapy, delivering alpha or beta emitters to target and destroy cancer cells.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Nvelop Therapeutics develops programmable delivery systems for in vivo gene editing and therapeutic cargo delivery. It combines epigenetic editing technologies with next-generation delivery methods to address unmet medical needs. The company focuses on genetic medicines designed to target cells and tissues within the body, aiming to treat severe genetic diseases by delivering gene-editing payloads to therapeutically relevant sites. Early efforts are aligned with enabling editing in cells and tissues that have been difficult to reach, with the objective of expanding the range of actionable genetic therapies. The company seeks to advance in vivo approaches that can improve precision and safety in delivering therapeutic cargo to patients.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

K36 Therapeutics develops small molecule therapeutics for cancer treatment. It translates epigenetic modulation of oncogenic pathways into small molecule therapies.

ARTBIO is a biotechnology company developing a new class of alpha radioligand medicines for cancer treatment. It focuses on radioligand therapy, delivering alpha or beta emitters to target and destroy cancer cells.

Adcentrx Therapeutics is a biotechnology company focused on protein conjugate therapeutics for cancer and other life-threatening diseases. The company seeks to accelerate breakthroughs in this field by combining the targeting precision of biologics with the potency of small-molecule payloads, enabling next-generation targeted therapies and expanding treatment options for patients.

Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.

SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. By collaborating with industry experts in technology and healthcare, as well as clinical leaders, parents, and payers, SpectrumAi aims to modernize the delivery of autism care. The company's innovative healthcare technology offers objective data, meaningful insights, and actionable recommendations, all designed to support patients in achieving optimal outcomes. These outcomes include fostering independent living, building meaningful relationships, pursuing lifelong vocational goals, and promoting self-advocacy. Through its efforts, SpectrumAi seeks to transform the landscape of autism treatment and improve the quality of life for individuals on the spectrum.

Cadence Neuroscience develops implantable medical device therapies for epilepsy, central pain, and other neurological disorders. Founded in 2017 and based in Redmond, Washington, the company pursues core technology developed at Mayo Clinic that is being evaluated clinically. The device detects brain signals and delivers electrical stimulation to modulate neural circuits, enabling personalized brain stimulation to improve seizure control relative to existing protocols.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

RIGImmune is a biopharmaceutical company dedicated to developing innovative immune-modulating therapies targeting RNA virus diseases and enhancing antitumor immune responses. The company focuses on creating novel treatments aimed at addressing a wide range of conditions associated with viral infections and certain cancers. Its therapeutic candidates are designed to improve treatment outcomes for viral respiratory infections, serving as adjuvants or boosters for healthcare providers. By advancing its research and development efforts, RIGImmune aims to contribute significantly to the treatment landscape for both viral and oncological diseases.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.

SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. By collaborating with industry experts in technology and healthcare, as well as clinical leaders, parents, and payers, SpectrumAi aims to modernize the delivery of autism care. The company's innovative healthcare technology offers objective data, meaningful insights, and actionable recommendations, all designed to support patients in achieving optimal outcomes. These outcomes include fostering independent living, building meaningful relationships, pursuing lifelong vocational goals, and promoting self-advocacy. Through its efforts, SpectrumAi seeks to transform the landscape of autism treatment and improve the quality of life for individuals on the spectrum.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. The company specializes in creating rapid diagnostic tests for infectious diseases, including a critical test for the detection of coronavirus infection. With a commitment to enhancing patient care, Proof Diagnostics designs and manufactures diagnostic kits that empower medical professionals to accurately and efficiently test patients for various infections. Additionally, the company is working on a smart, portable system aimed at expanding the capabilities of disease detection.

Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

K36 Therapeutics develops small molecule therapeutics for cancer treatment. It translates epigenetic modulation of oncogenic pathways into small molecule therapies.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Notable is an artificial intelligence platform for healthcare operations that automates administrative and operational tasks within health systems, clinics, and other care settings. The platform handles patient intake, scheduling, prior authorization, documentation, and billing automation, enabling providers and staff to streamline workflows and reduce manual workload for more efficient care delivery. It is deployed at over 10,000 sites of care and automates a million repetitive workflows daily across Registration and Intake, Scheduling and Referrals, Assistant, Authorizations, Care Gap Closure, and HCC Chart Review, leading to faster patient processing, improved care coordination, and stronger financial performance for healthcare organizations.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Proximie is a health technology company that enables surgeons worldwide to collaborate remotely using augmented reality, artificial intelligence, and machine learning. Its platform allows surgeons to visually guide complex surgeries, democratizing access to advanced surgical knowledge.

Founded in 2017, 1upHealth operates a health data aggregation platform that securely centralizes patient records from various electronic medical systems. Its platform enables patients to control and share their consolidated digital health record with providers, while also allowing developers to access clinical data from connected clinics and hospitals.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

J-Pharma specializes in developing novel pharmaceuticals based on a human-genomic approach. Its intellectual property focuses on cell membrane transporters linked to various diseases, enabling the creation of targeted drugs and diagnostic methods. The company aims to improve global health and enhance quality of life for aging populations by generating new drug agents.

Carrot Fertility, Inc. offers comprehensive fertility benefits services for employers, supporting employees throughout their fertility healthcare journey on a global scale. Founded in 2015 and headquartered in San Francisco, California, the company provides a range of services including egg freezing, in vitro fertilization, adoption, donor and gestational carrier services. It also features Carrot Rx, a premium pharmacy experience for fertility medications, and Carrot Pregnancy, which offers virtual access to experts and on-demand doctor-approved content. Additionally, Carrot Card is a flexible debit card that employees can use to pay for fertility care. Carrot Fertility aims to help companies customize their fertility benefits, ensuring that employees receive the necessary financial, medical, and emotional support as they pursue parenthood. The company has expanded its presence with additional offices in major cities including Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Arvelle Therapeutics GmbH is a biopharmaceutical company headquartered in Zug, Switzerland, founded in 2019. The company is dedicated to developing and commercializing innovative treatments for patients suffering from central nervous system (CNS) disorders. Its primary focus is on cenobamate, an investigational antiepileptic drug aimed at providing effective solutions for patients experiencing focal seizures. Through its efforts, Arvelle Therapeutics seeks to enhance the quality of care available to individuals affected by debilitating neurological and neuromuscular diseases.

Founded in 2016, Owkin is a French-American startup that uses artificial intelligence to enhance medical research. It develops machine learning tools to understand complex biology, identify new treatments, de-risk clinical trials, and develop diagnostics. Owkin's focus is improving drug discovery processes and patient outcomes.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.

Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. It employs its proprietary Smart Antibody Technology to enhance success rates, expedite time to market, and reduce development costs for therapeutic antibodies.

AviadoBio focuses on developing transformative gene therapies for devastating neurodegenerative disorders such as frontotemporal dementia and amyotrophic lateral sclerosis. The company's platform combines proprietary technologies with a deep understanding of the brain to deliver effective treatments.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Founded in 2016, Firefly Health delivers AI-driven virtual-first primary care. Its platform connects patients with healthcare professionals for convenient, continuous care, focusing on common conditions and women's health issues.

Buoy Health is a health technology company that develops AI-powered digital health tools to help individuals manage healthcare options. It offers an online healthcare assistant that analyzes symptoms, performs first-line triage, and provides treatment recommendations. Its platform delivers real-time symptom analysis and helps users navigate the healthcare system, research benefits, and locate in-network providers. For employers, the platform surfaces benefits information, guides employees to in-network providers, and integrates with other health portals. Founded in 2014 and based in Boston, Buoy Health aims to resemble a physician-patient conversation through machine learning and proprietary data, enabling users to make informed care decisions.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Founded in 2016, Owkin is a French-American startup that uses artificial intelligence to enhance medical research. It develops machine learning tools to understand complex biology, identify new treatments, de-risk clinical trials, and develop diagnostics. Owkin's focus is improving drug discovery processes and patient outcomes.

TreeENT Health is a specialized healthcare provider focused on ear, nose, and throat (ENT) services, established in 2017 and headquartered in Hangzhou, China. The company operates a chain of medical centers that cater to a variety of ENT conditions, including suppurative otitis media, allergic rhinitis, chronic sinusitis, and thyroid cancer. TreeENT Health utilizes advanced medical technologies, such as minimally invasive surgical techniques, internet-enabled services, and wearable medical devices, to enhance patient care. Their offerings include diagnostic services like Danish ear hearing detection, nasal endoscopy video examinations, and nasopharyngoscopy, along with personalized chronic disease rehabilitation. The integration of online appointment scheduling through platforms like WeChat facilitates convenient access to expert consultations and treatments, ensuring a high-quality experience for patients.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Founded in 2014, Genomics develops algorithms and software solutions focused on cancer, microbes, and rare diseases. Its solutions empower governments, healthcare providers, pharmaceutical companies, clinicians, and researchers to improve diagnoses, treatment options, and drug development processes through accurate genomic data analysis.

Modis Therapeutics, Inc. is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases characterized by high unmet medical needs. Incorporated in 2016 and based in Oakland, California, the company is known for its lead therapy, MT1621, which aims to restore mitochondrial DNA replication fidelity. This therapy specifically targets thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disorder. By improving nucleotide balance and increasing mitochondrial DNA copy number, Modis Therapeutics' approach seeks to enhance cellular function and prolong the lives of affected patients. As of September 2019, Modis Therapeutics operates as a subsidiary of Zogenix, Inc.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

Notable is an artificial intelligence platform for healthcare operations that automates administrative and operational tasks within health systems, clinics, and other care settings. The platform handles patient intake, scheduling, prior authorization, documentation, and billing automation, enabling providers and staff to streamline workflows and reduce manual workload for more efficient care delivery. It is deployed at over 10,000 sites of care and automates a million repetitive workflows daily across Registration and Intake, Scheduling and Referrals, Assistant, Authorizations, Care Gap Closure, and HCC Chart Review, leading to faster patient processing, improved care coordination, and stronger financial performance for healthcare organizations.

WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Orient Speech Therapy Center specializes in providing professional speech and language therapy services for children facing communication challenges, including those with autism or speech disorders. The center focuses on the early screening, clinical diagnosis, and therapeutic interventions essential for improving children's speech and social skills. It offers a range of refined curricula designed specifically for young learners, including the Star Curriculum, phonics and oral muscle courses, expression courses, and exercise classes. Through these structured programs, Orient Speech Therapy Center aims to enhance the communicative abilities of children, enabling them to express themselves more effectively and engage socially.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Buoy Health is a health technology company that develops AI-powered digital health tools to help individuals manage healthcare options. It offers an online healthcare assistant that analyzes symptoms, performs first-line triage, and provides treatment recommendations. Its platform delivers real-time symptom analysis and helps users navigate the healthcare system, research benefits, and locate in-network providers. For employers, the platform surfaces benefits information, guides employees to in-network providers, and integrates with other health portals. Founded in 2014 and based in Boston, Buoy Health aims to resemble a physician-patient conversation through machine learning and proprietary data, enabling users to make informed care decisions.

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients affected by fibrotic diseases. The company is built on significant scientific advancements and aims to address critical unmet medical needs in the fibrosis domain. By leveraging advanced understanding of the molecular mechanisms behind abnormal scarring, Indalo Therapeutics seeks to create treatments that can halt or even reverse fibrosis. The organization is comprised of a skilled team of pharmaceutical scientists and executives, dedicated to improving patient outcomes through novel therapeutic approaches.

PlasmaGen Biosciences Pvt. Ltd., established in 2010 and based in Bengaluru, India, is a biopharmaceutical company specializing in plasma protein therapies. The company manufactures a range of products including PlasmaGlob and AlbuMax, brands of Normal Human Immunoglobulin for Intravenous use, PlasmaRho-D I.V. for Rh immunization suppression, PlasmaRAB for rabies infection prophylaxis, PlasmaHep for hepatitis B exposure, VerBumin for conditions like hypovolemic shock and burns, and Gammafact-VIII. These products cater to various medical fields such as hematology, oncology, immunology, pediatrics, rheumatology, dermatology, and neurology. The company serves clinicians, medical practitioners, corporate hospitals, and government institutions.

Amphora Medical, Inc. is a Minnesota-based company that develops innovative medical devices aimed at treating female overactive bladder (OAB) syndrome. Founded in 2011 and headquartered in Maple Grove, Minnesota, the company is focused on creating a novel cystoscopic device that utilizes minimally invasive procedures to enhance bladder function. Amphora Medical's technology is designed to improve the quality of life for individuals suffering from OAB, offering a promising solution in the field of urology.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Genoa Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of idiopathic pulmonary fibrosis (IPF). It develops GP-101, an aerosol pirfenidone formulation for direct inhalation delivery to the lungs for the treatment of IPF. The company was founded in 2011 and is based in San Diego, California.

Medwell Ventures is a developer of a healthcare delivery platform designed to enhance accessibility and personalization in medical care. By integrating various delivery channels, the company focuses on providing specialty medical services in the home environment, particularly for chronic diseases outside traditional hospital settings. Utilizing a combination of healthcare expertise, advanced technology, and rigorous processes, Medwell Ventures aims to improve the accuracy and accountability of healthcare, ensuring that patients receive tailored treatments that cater to their specific health needs.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Founded in London in 2007, Pulmocide specializes in developing inhaled medicines targeting serious viral and fungal respiratory infections. Its focus is on creating drugs optimized for lung delivery to maximize efficacy while minimizing systemic exposure.

Celes Care is India's first online health clinic dedicated exclusively to women, based in Hyderabad. The company provides an accessible platform for women to receive healthcare consultations on various topics, including pregnancy care, nutrition, wellness, and general health. Celes Care connects patients with expert female doctors within a minute, ensuring that consultations are not only prompt but also compassionate and tailored to individual needs. By focusing on holistic healthcare, Celes Care aims to empower women with customized guidance in a supportive environment, making quality healthcare more affordable and convenient.

WelbeHealth serves frail seniors through its PACE (Program of All-Inclusive Care for the Elderly) model, providing comprehensive medical and social care. This enables participants to live better, longer, and more independently. The company coordinates various aspects of care, including medical appointments, therapy sessions, transportation, meals, and personal care services.

Avalyn Pharma is a biopharmaceutical company focused on developing therapies for severe respiratory diseases, notably idiopathic pulmonary fibrosis (IPF). Established in 2011, the company is headquartered in Seattle, Washington.